Liliana Sedova

Liliana Sedova

Auto-generated profile, based on publicly available information

Liliana Sedova

Institute of Rheumatology, Prague, Czech Republic

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2003 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
JVJ Vencovský
J Vencovský
SMS Macháček
S Macháček
LŠL Šedová
L Šedová
JKJ Kafková
J Kafková
JGJ Gatterová
J Gatterová
ŠRŠ Růžičková
Š Růžičková
Objective: To evaluate a contribution of selected laboratory parameters for a prediction of progressive and erosive development in patients with early rheumatoid arthritis (RA). Methods: In a prospective study baseline levels of antibodies to cyclic citrullinated peptide (anti-CCP), IgM, IgA, and IgG rheumatoid factors (RFs) were measured by enzyme linked immunosorbent assay (ELISA) in 104 patients with RA with disease duration 10 units. The combination of anti-CCP and IgM RF increased the ability to predict erosive and progressive disease. Conclusion: The data confirmed that measurement of anti-CCP, AKA, APF, and individual isotypes of RFs was useful for prediction of structural damage early in the disease course. Combined analysis of anti-CCP and IgM RF provides the most accurate prediction.

1 January 2005 in Arthritis Research & Therapy
Verified
Journal Article
Open access
ASAleksi Sedo
Aleksi Sedo
JDJonathan S. Duke-Cohan
Jonathan S. Duke-Cohan
EBEva Balaziova
Eva Balaziova
LSLiliana R Sedova
Liliana R Sedova
Several of the proinflammatory peptides involved in rheumatoid arthritis pathogenesis, including peptides induced downstream of tumor necrosis factor-α as well as the monocyte/T cell-attracting chemokines RANTES and stromal cell-derived factor (SDF)-1α and the neuropeptides vasoactive intestinal peptide (VIP) and substance P, have their biological half-lives controlled by dipeptidyl peptidase IV (DPPIV). Proteolysis by DPPIV regulates not only the half-life but also receptor preference and downstream signaling. In this article, we examine the role of DPPIV homologs, including CD26, the canonical DPPIV, and their substrates in the pathogenesis of rheumatoid arthritis. The differing specific activities of the DPPIV family members and their differential inhibitor response provide new insights into therapeutic design.

3 May 2010 in BMC Musculoskeletal Disorders
Verified
Journal Article
Open access
PDF file
RVRichard Vytášek
Richard Vytášek
LŠLiliana Šedová
Liliana Šedová
VVVladimír Vilím
Vladimír Vilím
Levels of pentosidine (representative of advanced glycation end-products) in sera of patients with rheumatoid arthritis are increased when compared with sera of other diagnoses or healthy controls. These levels have been reported to correlate with clinical indices of rheumatoid arthritis activity and with laboratory markers of inflammation. The purpose of this study was to find out if these findings pertain to other advanced glycation end-products. We have developed two immunoassays based on new monoclonal antibodies to advanced glycation end-products. Antibody 103-E3 reacts with an unidentified antigen, formed in the reaction of proteins with ribose, while antibody 8-C1 responds to Nε-(carboxyethyl)lysine. We have used these monoclonal antibodies to measure levels of advanced glycation end-products in sera of patients with rheumatoid arthritis, systemic lupus erythematosus, osteoarthritis, and healthy controls. We calculated the correlations between advanced glycation end-product levels in rheumatoid arthritis sera and the Disease Activity Score 28 (DAS28), age, disease duration, CRP, anti-CCP, rheumatoid factor and treatment with corticosteroids, respectively. Levels of both glycation products were significantly higher in sera of patients with rheumatoid arthritis when compared with sera of patients with systemic lupus erythematosus, osteoarthritis, or the healthy controls. Neither the level of Nε-(carboxyethyl)lysine nor the level of the 103-E3 antigen in rheumatoid arthritis sera correlated with the DAS28-scored rheumatoid arthritis activity. The levels of both antigens in rheumatoid arthritis sera did not correlate with age, gender, corticosteroid treatment, or levels of CRP, anti-CCP antibodies, and rheumatoid factor in sera. We report highly specific increases in the levels of two advanced glycation end-products in sera of patients with rheumatoid arthritis. This increase could be explained neither by rheumatoid arthritis activity nor by inflammation. We propose a working hypothesis that presumes the existence of a link between advanced glycation end-product formation and induction of autoimmunity.

1 September 2014 in Value in Health Regional Issues
Verified
Journal Article
Closed access
KKKlára Kruntorádová
Klára Kruntorádová
JKJiří Klimeš
Jiří Klimeš
LŠLiliana Šedová
Liliana Šedová
JŠJiří Štolfa
Jiří Štolfa
TDTomáš Doležal
Tomáš Doležal
APAlena Petříková
Alena Petříková

1 September 2014 in Value in Health Regional Issues
Verified
Journal Article
Closed access
JKJiří Klimeš
Jiří Klimeš
MVMilan Vocelka
Milan Vocelka
LŠLiliana Šedová
Liliana Šedová
TDTomáš Doležal
Tomáš Doležal
TMTomáš Mlčoch
Tomáš Mlčoch
JVJiří Vlček
Jiří Vlček

5 August 2010 in Clinica Chimica Acta
Verified
Journal Article
Closed access
LSLucie Sromova
Lucie Sromova
HMHelena Mareckova
Helena Mareckova
LSLiliana Sedova
Liliana Sedova
EBEva Balaziova
Eva Balaziova
ASAleksi Sedo
Aleksi Sedo